ERG and prostate carcinoma: A TMPRSS2:ERG translocation is detectable in ~50% of all prostate cancer foci [33,56], and results in overexpression of ERG (ETS Transcription Factor ERG) from exon 4 to 3′-end in >95% of TMPRSS2:ERG cases [57].